Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.

The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (CHOP Therapy) (14 days) for the treatment of non-hodgkin's lymphoma (NHL). The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of Non Hodgkin's Lymphoma (NHL). Rituximab to be included in CD20 positive patients.

Citation

(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day, 2024, version number 5a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6379/409_v5a_R_Chop_14_days.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-03-15	Health Service Executive	Indication approved for reimbursement.